SABS

SAB Biotherapeutics (SABS)

SAB Biotherapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SABS

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/21	06:45	GlobeNewswire Inc.	SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/05/06	20:15	GlobeNewswire Inc.	SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/04/16	20:15	GlobeNewswire Inc.	SAB Biotherapeutics Provides SAB-142 Trial Update	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/04/08	20:15	GlobeNewswire Inc.	SAB Biotherapeutics to Present at INNODIA Annual Meeting	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/04/04	20:15	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/03/29	20:15	GlobeNewswire Inc.	SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/03/25	23:15	GlobeNewswire Inc.	SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/03/09	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/24	06:55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/24	06:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/23	22:00	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/08	22:00	GlobeNewswire Inc.	SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/02	21:53	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/02/02	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Executive Leadership Change	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/27	06:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/27	06:00	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/26	07:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/24	07:58	GlobeNewswire Inc.	SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/20	06:21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/03	23:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2024/01/03	06:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/12/18	23:34	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/12/09	07:26	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/12/01	07:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	21:40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	21:30	GlobeNewswire Inc.	SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	06:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/29	06:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SABS	SAB Biotherapeutics Inc
2023/11/23	06:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SABS	SAB Biotherapeutics Inc